The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Promise of Molecular Medicine

The Promise of Molecular Medicine

September 19, 2018 • By Philip Seo

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In her recent editorial in Annals of the Rheumatic Diseases, Professor Maya H. Buch of the Leeds Institute and Musculo­skeletal Medicine outlines a few possibilities, including the following:6

You Might Also Like
  • Nanoparticle Medicine Delivery Shows Promise
  • HealthKit Wellness App Holds Promise for Medicine, Rheumatology
  • Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis
Explore This Issue
September 2018
Also By This Author
  • The Streets of Heaven: Remembering Nadia Morgan, MBBS
  • Innate vs. adaptive: myeloid-predominant vs. lymphoid-driven pathophysiology;
  • Autoimmunity vs. autoinflammatory: antibody vs. non-antibody-mediated disease; and
  • Stromal response: Exposure to drug modifies the disease.

Outside the observation that these patients exist, there is almost nothing known about them. Thus, the definition of refractory rheumatoid arthritis is, necessarily, pragmatic: Professor Buch suggests failure of at least one anticytokine and one cell-targeted biologic disease-modifying anti-rheumatic drug should qualify a patient for this sobriquet. Of course, the trouble is that clinically, it can take up to a year to determine whether a patient has refractory disease, and even longer to figure out the right drug or drugs to bring the disease under control. There has to be a better approach.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clearly, this [tumor agnostic] approach will turn into either the Facebook or the MySpace of the oncology world, & it is a little too early to say whether this approach will turn out to be the gamechanger we are all hoping for.

Agnosis as a Good Thing

In June 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab for the treatment of adult or pediatric patients with metastatic or unresectable solid tumors that are microsatellite instability high, meaning they have an impaired ability to repair DNA mismatch mutations.7 In theory, because of the increased rate of DNA mismatch repair defects, these tumors produce a large number of neoantigens, which could be targeted by immune checkpoint inhibitors. Of the 149 patients enrolled across five clinical trials, 39.6% had a complete or partial response to this drug. This doesn’t seem terribly remarkable, until you realize that all these patients had in common was their genetics. Patients who received treatment with pembrolizumab had a range of tumors, including colorectal, endometrial, pancreatic and other gastrointestinal cancers.8 It didn’t matter what type of cancer you had; your genetics predicted your response.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This was the first step toward the tumor agnostic approach to oncology you have been reading about over the past year. One such drug has already received FDA approval, one is currently under consideration by the FDA, and 10 more are under development by eight companies.9

Clearly, this approach will turn into either the Facebook or the MySpace of the oncology world, and it is a little too early to say whether this approach will turn out to be the game changer we are all hoping for. There are certainly naysayers, who believe the success of this approach relies on an unusual confluence of circumstances that is unlikely to be generalizable. Others cite unpublished data that will never make the light of day because they failed to make this approach work.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Rheuminations Tagged With: Genes, geneticsIssue: September 2018

You Might Also Like:
  • Nanoparticle Medicine Delivery Shows Promise
  • HealthKit Wellness App Holds Promise for Medicine, Rheumatology
  • Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis
  • Precision Medicine for Lupus Continues to Progress

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.